利莫那班
反激动剂
上瘾
医学
兴奋剂
不利影响
大麻素受体
大麻依赖
心理学
药理学
精神科
大麻
内科学
受体
大麻酚
作者
Omar Soler-Cedeño,Zheng‐Xiong Xi
出处
期刊:Cells
[MDPI AG]
日期:2022-10-17
卷期号:11 (20): 3262-3262
被引量:14
标识
DOI:10.3390/cells11203262
摘要
Cannabinoid receptor 1 (CB1R) has been one of the major targets in medication development for treating substance use disorders (SUDs). Early studies indicated that rimonabant, a selective CB1R antagonist with an inverse agonist profile, was highly promising as a therapeutic for SUDs. However, its adverse side effects, such as depression and suicidality, led to its withdrawal from clinical trials worldwide in 2008. Consequently, much research interest shifted to developing neutral CB1R antagonists based on the recognition that rimonabant's side effects may be related to its inverse agonist profile. In this article, we first review rimonabant's research background as a potential pharmacotherapy for SUDs. Then, we discuss the possible mechanisms underlying its therapeutic anti-addictive effects versus its adverse effects. Lastly, we discuss the rationale for developing neutral CB1R antagonists as potential treatments for SUDs, the supporting evidence in recent research, and the challenges of this strategy. We conclude that developing neutral CB1R antagonists without inverse agonist profile may represent attractive strategies for the treatment of SUDs.
科研通智能强力驱动
Strongly Powered by AbleSci AI